Patrys has today announced the completion of the first engineering run for its lead asset PAT-DX1.
The purification of PAT-DX1 from the cell harvest resulted in lower drug product recoveries than expected. Our team is now working with the Contract Development Manufacturing Organisation (CDMO) to implement improvements to the large-scale purification process.
This will mean an extension of the anticipated timeline to start our first in human study for PAT-DX1.